Advertisement

Topics

ALK-Abelló Company Profile

16:29 EST 21st November 2017 | BioPortfolio

ALK-Abelló is the world-leading producer of pharmaceuticals for specific allergy vaccination. Not only do our allergy vaccines treat the allergic symptoms, but also the underlying causes of allergy – and at the same time they prevent asthma.
ALK-Abelló has been active in allergy vaccination since 1923. In recent years, we have pursued a product development strategy of extending the current market of specialist administered subcutaneous vaccination to orally delivered alternatives. ALK-Abelló’s pipeline contains tablet-based products based on natural allergens against grass pollen and house dust mites.

ALK-Abelló has more than 1.200 employees with subsidiaries in several European countries, in the USA and in China. Headquarters is in Hoersholm, Denmark.

Location

Bøge Alle 6-8
Hørsholm
DK-2970
Denmark

Contact

Phone: (+45) 45 74 74 45
Fax: (+45) 45 74 86 90
Email: mailbox@dk.alk-abello.com


News Articles [11 Associated News Articles listed on BioPortfolio]

ALK-Abelló reports lower revenue for second quarter, blames capacity upgrades

Denmark-based allergy specialist ALK-Abelló has published its second quarterly results for the year,…

ALK-Abelló: ALK to accelerate launches of ODACTRA™ in the USA / ACARIZAX® in Canada

Copenhagen, 2017-08-21 18:59 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): -- The FDA has today transferred the US product licences for the SLIT-tablet portfolio to ALK allow...

ALK-Abelló: Management change at ALK

Copenhagen, 2017-07-31 10:11 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Flemming Pedersen, CFO and member of the Board of Management, has decided to re...

ALK-Abelló: Notification of ownership in ALK

Copenhagen, 2017-10-12 22:43 CEST (GLOBE NEWSWIRE) -- Pursuant to section 29 of the Danish Securities Trading Act, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) has received notification from Jupiter ...

ALK-Abelló: ALK's partner, Torii, gains approval for Japanese cedar SLIT-tablet in Japan

Copenhagen, 2017-09-27 09:00 CEST (GLOBE NEWSWIRE) -- -- CEDARCURE™ is the first SLIT-tablet to be approved for both adult and paediatric use in Japan -- Joins the already launched MITICURE™ (ACAR...

ALK-Abelló: ALK appoints Søren Jelert as new Chief Financial Officer

Copenhagen, 2017-11-03 09:26 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced the appointment of Søren Jelert as its new Chief Financial Officer (CFO) and Executiv.....

ALK-Abelló: ALK acts on French injunction by accelerating investments in its quality system at the French manufacturing facility

Copenhagen, 2017-09-21 19:39 CEST (GLOBE NEWSWIRE) -- ALK's 2017 full-year guidance remains unchanged.ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the French National Agency for ...

ALK-Abelló: Release date of six-month interim report (Q2) 2017 and audio cast

Copenhagen, 2017-08-08 15:39 CEST (GLOBE NEWSWIRE) -- On Wednesday, 16 August 2017, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its interim report for the six months ended 30 June 2017. ALK...

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Dog Hair Extract Study

Liquid allergen extracts contain proteins, such as (but not limited to) tree, weed, cat, cockroach, and nuts, and are used to identify allergies by observing the body's reaction to the int...

Companies [3 Associated Companies listed on BioPortfolio]

ALK-Abelló

ALK-Abelló is the world-leading producer of pharmaceuticals for specific allergy vaccination. Not only do our allergy vaccines treat the allergic symptoms, but also the underlying causes of allergy ...

DANSK BIOTEK

DANSK BIOTEK (The Danish Association of Biotechnology Industries) works to improve conditions for biotechnological research and production in Denmark, and to further the common interests of members, n...

Astex Therapeutics

Astex was founded in 1999 by Harren Jhoti, PhD, former Head of Structural Biology and of UK Bioinformatics at GlaxoWellcome, together with Professor Sir Tom Blundell, FRS, Professor Chris Abell, (both...

More Information about "ALK-Abelló" on BioPortfolio

We have published hundreds of ALK-Abelló news stories on BioPortfolio along with dozens of ALK-Abelló Clinical Trials and PubMed Articles about ALK-Abelló for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ALK-Abelló Companies in our database. You can also find out about relevant ALK-Abelló Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...


Corporate Database Quicklinks



Searches Linking to this Company Record